SRC SIGNALING IN CANCER


Caner A. , Asik E., Ozpolat B.

Tumor Microenvironmet-Siganling Pathways (B), Alexander Birbrair, Editör, Springer, London/Berlin , New-York, ss.23-33, 2020

  • Basım Tarihi: 2020
  • Yayınevi: Springer, London/Berlin 
  • Basıldığı Şehir: New-York
  • Sayfa Sayıları: ss.23-33
  • Editörler: Alexander Birbrair, Editör

Özet

Pioneering experiments performed by Harold Varmus and  Mike Bishop in 1976, led to one of  the most influential discoveries in cancer research and identified  the first cancer-causing oncogene called Src. Later experimental and clinical evidence suggested that Src kinase plays a significant role in promoting tumor growth and progression and its activity is assocated poor patient survival. Thus, several Src inhibitors were developed and approved by FDA for treatment of cancer patients. Tumor microenvironment (TME) is a highly complex  and  dynamic milieu  where significant cross-talk occurs  between cancer cells  and TME-components,  which consist of tumor-associated macrophages, fibroblasts, and other immune and vascular cells. Growth factors and chemokines activate multiple signaling cascades  in TME and induce multiple kinases and pathways, including Src, leading to tumor growth, invasion/metastasis, angiogenesis, drug resistance and progression. Here, we will sytemically evaluate recent findings regarding regulation of Src and significance of targeting Src in cancer therapy